Literature DB >> 14532091

Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.

John A Bogdan1, Wei Yuan, Karen O Long-Rowe, Jawad Sarwar, Eric Allen Brucker, M S Blake.   

Abstract

The introduction of acellular pertussis vaccines has greatly enhanced the safety profile of vaccines to prevent whooping cough. Pertussis toxin (Ptx) is one component produced by Bordetella pertussis that is contained in all of these vaccines, either in combination with other known pertussis virulence factors or as the sole pertussis component, combined with tetanus and diphtheria toxoids. A hydrogen peroxide toxoid of Ptx has been shown to be efficacious in preventing pertussis infections in a mass vaccination trial and is presently licensed in the United States and Europe (B. Trollfors, J. Taranger, T. Lagergard, L. Lind, V. Sundh, G. Zackrisson, C. U. Lowe, W. Blackwelder, and J. B. Robbins, N. Engl. J. Med. 333:1045-1050, 1995). The industrial production of Ptx can be performed through the cultivation of B. pertussis in well-defined growth media, in which the components can be well characterized and their origins can be documented. Once the bacteria are removed from the culture, Ptx can be isolated from the supernatant and purified by using the technique described by Sekura et al. (R. D. Sekura, F. Fish, C. R. Manclark, B. Meade, and Y. L. Zhang, J. Biol. Chem. 258:14647-14651, 1983). The only drawback of this procedure, which combines two affinity chromatography steps, one with Blue Sepharose and a second with matrix-bound bovine fetuin (BF), is the source and purity of the BF. Concern about vaccine preparations that may possibly risk contamination by material associated with bovine spongioform encephalopathy has continued to increase. We thus sought a replacement for the BF affinity chromatography and, more specifically, for the glycosidic moiety on BF. We describe here the identification of a seven-amino-acid peptide that mimics the glycosidic moiety on BF to which Ptx binds. Furthermore, we have constructed an affinity column containing this peptide that can be used to replace BF in Ptx purification. Finally, we used the X-ray crystallographic structure of Ptx bound to the oligosaccharide moiety of BF as a scaffold and replaced the oligosaccharide with the peptide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532091      PMCID: PMC201256          DOI: 10.1128/AEM.69.10.6272-6279.2003

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  17 in total

1.  Isolation of the lymphocytosis promoting factor-haemagglutinin of Bordetella pertussis by affinity chromatography.

Authors:  L I Irons; A P MacLennan
Journal:  Biochim Biophys Acta       Date:  1979-09-29

2.  A molecular basis for functional peptide mimicry of a carbohydrate antigen.

Authors:  P Luo; G Canziani; G Cunto-Amesty; T Kieber-Emmons
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

3.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

4.  Bordetella pertussis autoregulates pertussis toxin production through the metabolism of cysteine.

Authors:  J A Bogdan; J Nazario-Larrieu; J Sarwar; P Alexander; M S Blake
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase.

Authors:  R D Sekura; F Fish; C R Manclark; B Meade; Y L Zhang
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

6.  Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).

Authors:  M M Braun; G T Mootrey; M E Salive; R T Chen; S S Ellenberg
Journal:  Pediatrics       Date:  2000-10       Impact factor: 7.124

7.  Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.

Authors:  M Tamura; K Nogimori; S Murai; M Yajima; K Ito; T Katada; M Ui; S Ishii
Journal:  Biochemistry       Date:  1982-10-26       Impact factor: 3.162

8.  The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein.

Authors:  T Katada; M Tamura; M Ui
Journal:  Arch Biochem Biophys       Date:  1983-07-01       Impact factor: 4.013

9.  A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells.

Authors:  M Tamura; K Nogimori; M Yajima; K Ase; M Ui
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

10.  A placebo-controlled trial of a pertussis-toxoid vaccine.

Authors:  B Trollfors; J Taranger; T Lagergård; L Lind; V Sundh; G Zackrisson; C U Lowe; W Blackwelder; J B Robbins
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.